UBS Group’s Anterix ATEX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.83M | Sell |
47,875
-912
| -2% | -$28.9K | ﹤0.01% | 5058 |
|
|
2025
Q4 | $1.07M | Buy |
48,787
+3,166
| +7% | +$65.7K | ﹤0.01% | 5509 |
|
|
2025
Q3 | $979K | Sell |
45,621
-7,726
| -14% | -$173K | ﹤0.01% | 5592 |
|
|
2025
Q2 | $1.37M | Sell |
53,347
-1,467
| -3% | -$42.9K | ﹤0.01% | 5169 |
|
|
2025
Q1 | $2.01M | Sell |
54,814
-5,414
| -9% | -$186K | ﹤0.01% | 4700 |
|
|
2024
Q4 | $1.85M | Buy |
60,228
+53,569
| +804% | +$1.78M | ﹤0.01% | 4796 |
|
|
2024
Q3 | $251K | Sell |
6,659
-1,114
| -14% | -$42.9K | ﹤0.01% | 5704 |
|
|
2024
Q2 | $308K | Sell |
7,773
-6,873
| -47% | -$222K | ﹤0.01% | 5381 |
|
|
2024
Q1 | $492K | Buy |
14,646
+9,816
| +203% | +$330K | ﹤0.01% | 5224 |
|
|
2023
Q4 | $161K | Buy |
4,830
+4,523
| +1,473% | +$146K | ﹤0.01% | 5903 |
|
|
2023
Q3 | $9.63K | Sell |
307
-9,210
| -97% | -$290K | ﹤0.01% | 7128 |
|
|
2023
Q2 | $302K | Buy |
9,517
+2,815
| +42% | +$91K | ﹤0.01% | 5204 |
|
|
2023
Q1 | $221K | Buy |
6,702
+52
| +0.8% | +$1.7K | ﹤0.01% | 5312 |
|
|
2022
Q4 | $214K | Buy |
6,650
+6,184
| +1,327% | +$211K | ﹤0.01% | 5398 |
|
|
2022
Q3 | $17K | Sell |
466
-1,255
| -73% | -$52.1K | ﹤0.01% | 7583 |
|
|
2022
Q2 | $71K | Sell |
1,721
-1,129
| -40% | -$54.8K | ﹤0.01% | 5666 |
|
|
2022
Q1 | $165K | Sell |
2,850
-2,425
| -46% | -$133K | ﹤0.01% | 5505 |
|
|
2021
Q4 | $310K | Buy |
5,275
+4,660
| +758% | +$283K | ﹤0.01% | 5351 |
|
|
2021
Q3 | $37K | Sell |
615
-1,159
| -65% | -$68K | ﹤0.01% | 6562 |
|
|
2021
Q2 | $107K | Sell |
1,774
-327
| -16% | -$16.4K | ﹤0.01% | 5825 |
|
|
2021
Q1 | $99K | Sell |
2,101
-275
| -12% | -$11.3K | ﹤0.01% | 5974 |
|
|
2020
Q4 | $89K | Buy |
2,376
+1,938
| +442% | +$63.9K | ﹤0.01% | 5756 |
|
|
2020
Q3 | $14K | Sell |
438
-4,953
| -92% | -$210K | ﹤0.01% | 6569 |
|
|
2020
Q2 | $244K | Buy |
5,391
+814
| +18% | +$41.6K | ﹤0.01% | 4659 |
|
|
2020
Q1 | $209K | Sell |
4,577
-8,859
| -66% | -$401K | ﹤0.01% | 4688 |
|
|
2019
Q4 | $581K | Buy |
13,436
+6,300
| +88% | +$257K | ﹤0.01% | 4702 |
|
|
2019
Q3 | $258K | Buy |
7,136
+4,514
| +172% | +$190K | ﹤0.01% | 5050 |
|
|
2019
Q2 | $123K | Buy |
2,622
+2,472
| +1,648% | +$104K | ﹤0.01% | 5244 |
|
|
2019
Q1 | $5K | Sell |
150
-4,281
| -97% | -$168K | ﹤0.01% | 7145 |
|
|
2018
Q4 | $166K | Buy |
4,431
+776
| +21% | +$30.3K | ﹤0.01% | 5105 |
|
|
2018
Q3 | $124K | Buy |
3,655
+2,455
| +205% | +$71.8K | ﹤0.01% | 5395 |
|
|
2018
Q2 | $30K | Buy |
1,200
+450
| +60% | +$12.5K | ﹤0.01% | 6374 |
|
|
2018
Q1 | $22K | Sell |
750
-502
| -40% | -$16.8K | ﹤0.01% | 6342 |
|
|
2017
Q4 | $40K | Buy |
1,252
+845
| +208% | +$27.2K | ﹤0.01% | 6022 |
|
|
2017
Q3 | $12K | Sell |
407
-281
| -41% | -$7.69K | ﹤0.01% | 6767 |
|
|
2017
Q2 | $16K | Sell |
688
-1,604
| -70% | -$37.3K | ﹤0.01% | 6455 |
|
|
2017
Q1 | $50K | Buy |
2,292
+437
| +24% | +$9.88K | ﹤0.01% | 5523 |
|
|
2016
Q4 | $42K | Buy |
+1,855
| New | +$44.8K | ﹤0.01% | 5960 |
|
|
2016
Q2 | – | Sell |
-1,578
| Closed | -$54K | – | 7705 |
|
|
2016
Q1 | $54K | Buy |
+1,578
| New | +$41.7K | ﹤0.01% | 5443 |
|
|
2015
Q4 | – | Sell |
-1,000
| Closed | -$30K | – | 8324 |
|
|
2015
Q3 | $30K | Buy |
+1,000
| New | +$32.7K | ﹤0.01% | 6277 |
|
|
2015
Q2 | – | Sell |
-168
| Closed | -$8K | – | 8468 |
|
|
2015
Q1 | $8K | Buy |
+168
| New | +$8.17K | ﹤0.01% | 7795 |
|
Other funds holding ATEX
OCAM
HCL
VCM
QF
PM
GI
UBS Group's ATEX Position: Q1 2026 in Review
UBS Group reduced its Anterix (ATEX) stake by 1.9% in Q1 2026, selling an estimated $28.9K and leaving 47,875 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #5058.
UBS Group first reported a position in ATEX in Q1 2015 and has held it in 41 quarters since. The position peaked at $2.01M in Q1 2025. 132 funds tracked by Wall St. Rank hold ATEX as of Q1 2026.
- UBS Group held 47,875 shares of Anterix worth $1.83M as of Q1 2026.
- UBS Group sold 912 Anterix shares in Q1 2026, an estimated $28.9K.
- Anterix made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5058 holding.
- UBS Group first reported a position in Anterix in Q1 2015 and has held it in 41 quarters since.
- UBS Group's Anterix position peaked at $2.01M in Q1 2025.
- 132 funds tracked by Wall St. Rank held Anterix as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.